[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650447":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":11,"centralContacts":11,"locations":44,"responsibleParty":63,"collaborators":11,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":11,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":11,"enrollmentInfo":76,"targetDuration":11,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":11,"overallStatus":85,"whyStopped":11,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"University of Medicine and Pharmacy at Ho Chi Minh City","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Metronidazole-Based Bismuth Quadruple Therapy","ACTIVE_COMPARATOR",null,[13,14,15,16],"Drug: Metronidazole","Drug: tetracyline","Drug: Bismuth Subcitrate","Drug: esomeprazole 40 mg",{"label":18,"type":19,"description":11,"interventionNames":20},"Tinidazole-Based Bismuth Quadruple Therapy","EXPERIMENTAL",[21,14,15,16],"Drug: Tinidazole 500mg",[23,28,32,36,40],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","Metronidazole","Metronidazole 500 mg orally three times daily after meals for 14 days, administered as part of bismuth quadruple therapy with esomeprazole 40 mg twice daily, tetracycline 500 mg four times daily, and bismuth subcitrate 120 mg four times daily.",[9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":11},"Tinidazole 500mg","Tinidazole 500 mg orally three times daily after meals for 14 days, administered as part of bismuth quadruple therapy with esomeprazole 40 mg twice daily, tetracycline 500 mg four times daily, and bismuth subcitrate 120 mg four times daily.",[18],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":11},"tetracyline","Tetracyline 500 mg four times daily",[9,18],{"type":24,"name":37,"description":38,"armGroupLabels":39,"otherNames":11},"Bismuth Subcitrate","120 mg four times daily",[9,18],{"type":24,"name":41,"description":42,"armGroupLabels":43,"otherNames":11},"esomeprazole 40 mg","40 mg twice daily",[9,18],[45],{"facility":5,"status":11,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Ho Chi Minh City","Ho Chi Minh","70000","Vietnam","VN",{"type":52,"coordinates":53},"Point",[54,55],106.62965,10.82302,{"lat":55,"lon":54},[58],{"name":59,"role":60,"phone":61,"phoneExt":11,"email":62},"Nhu Vu","CONTACT","+84-907513827","vuhanhnhu@ump.edu.vn",{"type":64,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Nhu Thi Hanh Vu","Lecturer","100650447","metronidazole--versus-tinidazole-based-bismuth-quadruple-therapy-for-helicobacter-pylori-eradication-100650447",false,"NCT07746934","Metronidazole- Versus Tinidazole-Based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication","Comparison of Metronidazole- and Tinidazole-Based Bismuth Quadruple Regimens for Helicobacter Pylori Eradication","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Confirmed Helicobacter pylori infection\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Gastrointestinal malignancy.\n* Previous H. pylori eradication therapy.\n* Liver cirrhosis.\n* Stage IV or V chronic kidney disease.\n* Previous gastric surgery.\n* Known allergy to any study medication.\n* Use of antibiotics within the previous 4 weeks.","ALL","18 Years",{"count":77,"type":78},600,"ESTIMATED","INTERVENTIONAL",[81],"NA","This randomized, open-label clinical trial will compare two bismuth-containing quadruple therapies for the first-line treatment of Helicobacter pylori infection. Adults aged 18 years or older with confirmed H. pylori infection who have not previously received eradication treatment will be randomly assigned in a 1:1 ratio to receive either a metronidazole-based regimen or a tinidazole-based regimen for 14 days. Both regimens will also include esomeprazole, tetracycline, and bismuth subcitrate.\n\nThe main purpose of the study is to determine whether the tinidazole-based regimen is not inferior to the metronidazole-based regimen in achieving successful H. pylori eradication. Eradication will be assessed after treatment using a carbon-13 urea breath test or an endoscopic urease test. The study will also compare adverse effects and treatment tolerability between the two groups. The results may help clinicians select the more appropriate nitroimidazole for bismuth quadruple therapy in routine clinical practice.",[84],"Helicobacter Pylori Infection","NOT_YET_RECRUITING","2026-07-30",{"date":88,"type":89},"2026-08-05","ACTUAL",{"date":91,"type":78},"2026-07-27",{"date":93,"type":78},"2027-12-27",{"name":5,"class":6},1]